Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis

Company Overview

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Key Stats

• Today's Range: $0.06 to $0.08
• 50-Day Range: $0.04 to $0.09
• 52-Week Range: $0.03 to $0.08
• Volume: 118,925 shs
• Average Volume: 188,331 shs
• Market Capitalization: $732.98 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HEPA Stock Analysis - Frequently Asked Questions

How have HEPA shares performed this year?

Hepion Pharmaceuticals' stock was trading at $23.5050 at the start of the year. Since then, HEPA stock has decreased by 99.7% and is now trading at $0.0641.

How were Hepion Pharmaceuticals' earnings last quarter?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) issued its quarterly earnings results on Sunday, November, 15th. The company reported ($690.00) earnings per share for the quarter, missing analysts' consensus estimates of ($510.00) by $180.00.

When did Hepion Pharmaceuticals' stock split?

Hepion Pharmaceuticals shares reverse split on the morning of Tuesday, March 18th 2025.The 1-50 reverse split was announced on Friday, March 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Hepion Pharmaceuticals?

Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hepion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), FuelCell Energy (FCEL), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/15/2020
• Today: 8/09/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HEPA
• CIK: 1583771
• Web: www.hepionpharma.com
• Phone: (732) 902-4000
• Fax: 732-902-4100
• Employees: 20
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($219.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.93 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -812.56%
• Return on Assets: -207.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.30
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 11,435,000
• Free Float: 6,631,000
• Market Cap: $732.98 thousand
• Optionable: No Data
• Beta: 1.52